Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (February 2023)
16 slides from Genetic Signatures's investor presentation, Feb 2, 2023
Slide 1: Investor Update February 2023
For personal use only Investor Update February 2023
Slide 2: Disclaimer
Q2Q2 FY23 FY23 MARKET MarketUPDATE Update Disclaimer February 2023 This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It comprises written For personal use only materials/slides for a verbal prese
Slide 3: Investment highlights
Investment highlights Q2Q2 FY23 FY23 MARKET MarketUPDATE Update February 2023 Proprietary 3base® technology platform - a revolutionary approach for For personal use only molecular diagnostics Dramatically simplifies multiple pathogen testing from a single sample (multiplexing); more informative—simp
Slide 4: Company Snapshot
Q2Q2 FY23 FY23 MARKET MarketUPDATE Update Company Snapshot February 2023 For personal use only Financial information Share price (31-Jan-23) A$0.88 Shares on issue 143.4m Market capitalisation A$126.2m Cash (31-Dec-22) A$26.8m Debt (30-Dec-22) Nil Enterprise value A$99.4m Top shareholders % Research
Slide 5: Strong underlying growth in core revenue streams
Strong underlying growth in core revenue streams Q2Q2 FY23 FY23 MARKET MarketUPDATE Update February 2023 Sales Revenue (A$m) Q2 FY23 sales $4.7 million, H1 FY23 sales $10.4 million For personal use only • Anticipated material decline in pathogen-specific molecular testing for SARS-CoV-2 experienced
Slide 6: Robust underlying growth though pandemic
Robust underlying growth though pandemic Q2Q2 FY23 FY23 MARKET MarketUPDATE Update February 2023 Sales Revenue (A$m) Covid “sugar hit” For personal use only • Revenues in FY21 & FY22 were significantly boosted by Covid molecular test sales during pandemic Pandemic sales • Inevitable decline in sales
Slide 7: Revenue dominated by sale of syndromic tests
Revenue dominated by sale of syndromic tests Q2Q2 FY23 FY23 MARKET MarketUPDATE Update February 2023 Sales mix returning to syndromic tests focus For personal use only Sales Revenue (A$m) • Ensured Company continued to build sales of syndromic tests throughout pandemic while benefitting from Covid o
Slide 8: Robust pipeline with multiple products cleared for sale
Robust pipeline with multiple products cleared for sale Q2Q2 FY23 FY23 MARKET MarketUPDATE Update February 2023 For personal use only DEVELOPMENT RESEARCH USE REGISTRATION TGA CE Mark FDA planned in progress (expect 2023) Converting to new protocol planned planned In development 8
Slide 9: Enteric Protozoan kit will provide entry to North America
Enteric Protozoan kit will provide entry to North America Q2Q2 FY23 FY23 MARKET MarketUPDATE Update February 2023 High need for Enteric Protozoan Kit For personal use only • 5.5 million tests conducted in the US pa • Primarily culture/microscopy: slow, labour intensive, unreliable • Detects leading
Slide 10: US 510(k) for Enteric Protozoan filing by end of April
US 510(k) for Enteric Protozoan filing by end of April Q2Q2 FY23 FY23 MARKET MarketUPDATE Update February 2023 Final steps underway For personal use only • Recruitment for trial involving 1,500 clinical samples was completed in July 2022 • As several of the assays are not included in the predicate d
Slide 11: Growth initiatives
Growth initiatives Q2Q2 FY23 FY23 MARKET MarketUPDATE Update February 2023 Leverage experience in AU market to grow international sales For personal use only • Europe – drive adoption of other 3base® products • US – build 3base® franchise once Protozoan Detection Kit is cleared Build & expand portfo
Slide 12: Upcoming milestones
Upcoming milestones – 12 months Q2Q2 FY23 FY23 MARKET MarketUPDATE Update February 2023 For personal use only US Enteric Protozoan Kit • File 510(k) application April 2023 • Launch product once clearance is granted Increase sales and presence in UK and European markets • Contracts with new customers
Slide 13: Contact Us
For personal use only Contact Us Dr John Melki Genetic Signatures Ltd Chief Executive Officer E: john.melki@geneticsignatures.com P: +61 (0)2 9870 7580 Visit us www.geneticsignatures.com Follow us 13
Slide 14: Appendices
Q2Q2 FY23 FY23 MARKET MarketUPDATE Update February 2023 For personal use only APPENDICES 14
Slide 15: How 3base simplifies molecular targets
Q2Q2 FY23 FY23 MARKET MarketUPDATE Update How 3base® simplifies molecular targets February 2023 For personal use only Molecular diagnostic tests are based on DNA/RNA sequences • DNA/RNA is unique to each organism. Genetic Signatures 3base® makes multiplex testing easier: • More informative – detect
Slide 16: 3base simplifies Syndromic Testing – EasyScreen Kits
3base® simplifies Syndromic Testing – EasyScreen™ Kits For personal use only Q2Q2 FY23 FY23 MARKET MarketUPDATE Update February 2023 Syndromic testing: simultaneously test for multiple pathogens that all can cause the same signs and symptoms • Respiratory infections: cough, runny nose, sore throat,
Genetic Signatures — Investor Presentation (February 2023) on 6ix